Project Grant R01AI199483
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $451,000 to the University of California, San Francisco under the Allergy and Infectious Diseases Research program (CFDA 93.855) on August 15, 2025, with completion scheduled for July 31, 2027. This Project Grant supports the development and application of high-resolution phage immunoprecipitation sequencing (PhIP-Seq) arrays designed to comprehensively evaluate antibody responses to...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded UCSF a $1.35 million Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective August 11, 2025, through July 31, 2030. The award funds research to characterize interactions between human and vector behaviors to enhance malaria control interventions in Uganda. The project addresses a critical public health gap: while insecticide-treated bed nets (ITNs) and...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $246,000 Project Grant to The Regents of the University of California, San Francisco under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period May 1, 2026 through April 30, 2028. This research initiative, titled "Malaria Importation and the Role of Agriculture in Local Transmission in Eswatini (MIRA)," delivers advanced parasitological and...
- Federal Grant Award Summary The University of California, San Francisco (UCSF) received a $895,740 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize CD4 T cells targeting liver and blood stage malaria epitopes. The five-year project, awarded February 2, 2026, and concluding January 31, 2031, addresses critical gaps in malaria vaccine development by identifying hundreds of...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Leland Stanford Junior University a Project Grant totaling $789,442 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 17, 2025, with a completion date of June 30, 2030. This research initiative employs multi-omics approaches—including single-cell proteomic and transcriptomic analyses—to investigate how the immune system adapts to repeated Plasmodium...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $823,548 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of California, Irvine on May 11, 2026, with a completion date of April 30, 2031. This collaborative research initiative focuses on developing antimalarial and antibabesial clinical candidates based on leelamine-derived isonitriles, specifically the lead compound GB-79. The research...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Washington University a Project Grant of $545,236 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 16, 2025, with a completion date of January 31, 2027. This award funds research investigating heme homeostasis mechanisms in the malaria parasite Plasmodium falciparum, addressing a critical global health challenge—malaria remains the deadliest...
- Federal Project Grant Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Washington University a Project Grant of $107,542 under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period September 1, 2025, through August 31, 2027. The award supports investigator-initiated biomedical research examining the differential sorting and trafficking mechanisms of Plasmodium falciparum secreted proteins, with particular focus on how...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Hennepin Healthcare Research Institute a Project Grant totaling $661,037 under the Allergy and Infectious Diseases Research program (CFDA 93.855) beginning May 1, 2026 and concluding April 30, 2031. This research initiative focuses on enhancing T cell and B cell immune responses to Plasmodium parasites through interleukin-15 (IL-15) cytokine-based therapy to address critical gaps in...
- Federal Grant Award Summary Seattle Children's Research Institute received a $516,175 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on June 23, 2025, with a completion date of May 31, 2027. The award funds research evaluating the impact of pre-existing humoral immunity on hepatocyte death in the context of malaria infection and vaccine efficacy. The research addresses a...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded $810,125 to The Regents of the University of California, San Francisco under the Allergy and Infectious Diseases Research program (CFDA 93.855) on June 9, 2026, for a project period extending through May 31, 2031. This Project Grant funds a comprehensive research evaluation of Plasmodium falciparum infection and naturally acquired immunity (NAI) in samples collected from a Ugandan birth cohort of 924 children randomized to receive either placebo or highly effective perennial malaria chemoprevention (PMC) with dihydroartemisinin-piperaquine through age 1-2 years, with follow-up through age 4 years. The research will deliver scientific outputs characterizing how PMC affects the development of pre-erythrocytic and blood-stage immunity over time through application of ultra-sensitive quantitative polymerase chain reaction (PCR), amplicon sequencing, and high-resolution antibody profiling. Key deliverables include genotyping of all P. falciparum infections in the cohort to estimate molecular force of infection (MFOI) and comparative analysis of MFOI differences between treatment arms following chemoprevention cessation, thereby generating evidence to resolve inconsistent findings regarding rebound malaria risk and sustained protection following PMC withdrawal in early childhood malaria immunity development.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $810.1k | 6/9/26 |